BioCentury
ARTICLE | Finance

First in fall

Cempra is first U.S. biotech in IPO queue in fall 2011, files to raise $86.3M

October 17, 2011 7:00 AM UTC

Cempra Holdings LLC is the first U.S. biotech to propose an IPO since July. The antibiotics company, which filed to raise $86.3 million, hopes to use the funds for Phase III testing of two candidates in 2H12: solithromycin and Taksta fusidic acid.

Solithromycin (CEM-101) is an oral macrolide antibiotic for community-acquired bacterial pneumonia (CABP). Taksta fusidic acid (CEM-102) is an oral antibiotic against Gram-positive bacteria for acute bacterial skin and skin structure infections (aBSSSIs)...